Business Group Blog

The Future of Genetic Testing & Treatments: Approaching the Tipping Point

Last week, 120 employers and industry leaders came together in Washington, DC for the NBGH Employers’ Summit on Health Care Costs & Solutions. Attendees had the opportunity to hear from Dr. Kathryn Phillips, founder and director of the UCSF Center for Translational and Policy Research on Personalized Medicine regarding the evolving landscape of genetic tests and treatments and the ways to evaluate their economic value.

While precision medicine and genetic testing are not new to the health care landscape, the sheer number of tests and the cost of treatments available has skyrocketed recently – with 10 new genetic tests entering the U.S. market daily.

Dr. Phillips also discussed the All of Us Research Program – the most expansive research project of its kind – funded by the National Institutes of Health (NIH). The program aims to accelerate research in precision medicine by gathering data from 1 million or more people living in the U.S.  More significantly, it was recently announced that the program would pilot the return of genetic test results back to participants, including pharmacogenetic and disease-associated variants as recommended by the American College of Medical Genetics and Genomics.

Genetic testing coverage is new, largely uncharted territory for employers. From simply sorting through the countless test offerings on the market to determining which ones carry the most promise from a cost and quality of care perspective, employers have their work cut out for them, but are anxious to learn more.

The precision medicine conversation will continue at Business Health Agenda 2019, this time with a deeper focus on how science has brought oncology treatment to a whole new level, including, for example, a drug recently approved by Food and Drug Administration to treat a wide range of cancers based on a shared mutation, rather than tumor location.

There has never been a time when innovation has brought so much promise to cancer treatment. Join us from April 10-12 in Washington, DC to hear from leading experts on how to navigate the latest oncology advancements and guide your members to the best, most cost-effective treatment available. Register and secure your seat today - Early Bird ends next Monday, February 4th!